Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Rheumatoid Arthritis

  Free Subscription


Articles published in Ann Rheum Dis

Retrieve available abstracts of 333 articles:
HTML format



Single Articles


    March 2024
  1. COHEN P, Ziff D, Lipsky PE
    Morris Ziff.
    Ann Rheum Dis. 2024;83:417-420.
    PubMed    


  2. WINTHROP KL, Mease P, Kerschbaumer A, Voll RE, et al
    Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023.
    Ann Rheum Dis. 2024;83:409-416.
    PubMed     Abstract available


  3. MELOKHINA V, Paulshus Sundlisaeter N, Sexton J, Sundin U, et al
    Subclinical inflammation and joint damage progression in patients with early RA fulfilling 2011 vs 2022 ACR/EULAR Boolean remission criteria: data from the ARCTIC study.
    Ann Rheum Dis. 2024;83:540-541.
    PubMed    


    February 2024
  4. HE Y, Aoun M, Xu Z, Holmdahl R, et al
    Shift in perspective: autoimmunity protecting against rheumatoid arthritis.
    Ann Rheum Dis. 2024 Feb 27:ard-2023-225237. doi: 10.1136/ard-2023-225237.
    PubMed     Abstract available


  5. VAN DER WOUDE D, Toes REM
    Immune response to post-translationally modified proteins in rheumatoid arthritis: what makes it special?
    Ann Rheum Dis. 2024 Feb 20:ard-2023-224103. doi: 10.1136/ard-2023-224103.
    PubMed     Abstract available



  6. Correction: Genetic variants in IL15 associate with progression of joint destruction in rheumatoid arthritis: a multicohort study.
    Ann Rheum Dis. 2024;83:e8.
    PubMed    



  7. Correction: A genetic variant in the region of MMP-9 is associated with serum levels and progression of joint damage in rheumatoid arthritis.
    Ann Rheum Dis. 2024;83:e9.
    PubMed    


  8. TANG Z, Shi H, Liu HL, Cheng X, et al
    Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria'.
    Ann Rheum Dis. 2024;83:e4.
    PubMed    


  9. BARBHAIYA M, Zuily S, Hendry AM, Manneville F, et al
    Response to: Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria' by Tang et al.
    Ann Rheum Dis. 2024;83:e5.
    PubMed    


  10. DAMOISEAUX J, van Beers J
    Correspondence on "ACR/EULAR antiphospholipid syndrome classification criteria".
    Ann Rheum Dis. 2024;83:e6.
    PubMed    


  11. ERKAN D, Barbhaiya M, Zuily S, Bertolaccini ML, et al
    Response to: Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria' by Miro-Mur et al.
    Ann Rheum Dis. 2024;83:e3.
    PubMed    


  12. BARBHAIYA M, Zuily S, Bertolaccini ML, Willis R, et al
    Response to: Correspondence on 'ACR/EULAR antiphospholipid syndrome classification criteria' by Damoiseaux and van Beers.
    Ann Rheum Dis. 2024;83:e7.
    PubMed    


  13. MIRO-MUR FA, Alijotas-Reig J, Anunciacion-Llunell A, Marques-Soares J, et al
    Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria'.
    Ann Rheum Dis. 2024;83:e2.
    PubMed    


  14. PEZOT M, Nocturne G, Belkhir R, Henry J, et al
    Obinutuzumab in patients with Sjogren's disease immunised against rituximab.
    Ann Rheum Dis. 2024;83:407-408.
    PubMed    


  15. DORNER T, Kaul M, Szanto A, Tseng JC, et al
    Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjogren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
    Ann Rheum Dis. 2024;83:360-371.
    PubMed     Abstract available


  16. CROWSON CS, Atkinson EJ, Kronzer VL, Kimbrough BA, et al
    Comorbidity clusters in patients with rheumatoid arthritis identify a patient phenotype with a favourable prognosis.
    Ann Rheum Dis. 2024 Feb 8:ard-2023-225093. doi: 10.1136/ard-2023-225093.
    PubMed     Abstract available


  17. SCHENNING LCM, Ottevanger R, Quint KD, Tas SW, et al
    An ulcerating skin tumour in a patient with rheumatoid arthritis.
    Ann Rheum Dis. 2024 Feb 5:ard-2023-225436. doi: 10.1136/ard-2023-225436.
    PubMed    


  18. HU F, Shi L, Liu X, Chen Y, et al
    Proinflammatory phenotype of B10 and B10pro cells elicited by TNF-alpha in rheumatoid arthritis.
    Ann Rheum Dis. 2024 Feb 1:ard-2023-224878. doi: 10.1136/ard-2023-224878.
    PubMed     Abstract available


    January 2024
  19. WU G, Cao B, Zhai H, Liu B, et al
    EPO promotes the progression of rheumatoid arthritis by inducing desialylation via increasing the expression of neuraminidase 3.
    Ann Rheum Dis. 2024 Jan 25:ard-2023-224852. doi: 10.1136/ard-2023-224852.
    PubMed     Abstract available


  20. HECKERT SL, Maassen JM, le Cessie S, Goekoop-Ruiterman YPM, et al
    Long-term mortality in treated-to-target RA and UA: results of the BeSt and IMPROVED cohort.
    Ann Rheum Dis. 2024;83:161-168.
    PubMed     Abstract available


  21. BONELLI M, Kerschbaumer A, Kastrati K, Ghoreschi K, et al
    Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.
    Ann Rheum Dis. 2024;83:139-160.
    PubMed     Abstract available


  22. TANAKA H, Okada Y, Nakayamada S, Miyazaki Y, et al
    Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping.
    Ann Rheum Dis. 2024;83:242-252.
    PubMed     Abstract available


  23. DREHER M, Witte T, Hoeper K, Assmann G, et al
    Rheuma-VOR study: optimising healthcare of rheumatic diseases by multiprofessional coordinating centres.
    Ann Rheum Dis. 2024;83:184-193.
    PubMed     Abstract available


  24. SCHIFF AE, Wang X, Patel NJ, Kawano Y, et al
    Immunomodulators and risk for breakthrough COVID-19 after third SARS-CoV-2 mRNA vaccine among patients with rheumatoid arthritis: a cohort study.
    Ann Rheum Dis. 2024 Jan 10:ard-2023-225162. doi: 10.1136/ard-2023-225162.
    PubMed    


  25. AVOUAC J, Hecquet S, Thomas M, Combier A, et al
    Validation of the definition of rheumatoid arthritis flare based on SDAI and CDAI in clinical practice in two French independent cohorts.
    Ann Rheum Dis. 2024 Jan 5:ard-2023-225272. doi: 10.1136/ard-2023-225272.
    PubMed    


  26. TEUWEN MMH, van Weely SFE, Vliet Vlieland TPM, van Wissen MAT, et al
    Effectiveness of longstanding exercise therapy compared with usual care for people with rheumatoid arthritis and severe functional limitations: a randomised controlled trial.
    Ann Rheum Dis. 2024 Jan 3:ard-2023-224912. doi: 10.1136/ard-2023-224912.
    PubMed     Abstract available


  27. BAKER JF, ODell JR, England BR, Giles JT, et al
    Lower body mass and lower adiposity are associated with differential responses to two treatment strategies for rheumatoid arthritis.
    Ann Rheum Dis. 2024 Jan 3:ard-2023-225014. doi: 10.1136/ard-2023-225014.
    PubMed     Abstract available



  28. Correction: Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration.
    Ann Rheum Dis. 2024;83:e1.
    PubMed    


  29. CAO S, Li Y, Song R, Meng X, et al
    L-arginine metabolism inhibits arthritis and inflammatory bone loss.
    Ann Rheum Dis. 2024;83:72-87.
    PubMed     Abstract available


  30. BIJLSMA JWJ
    Annals of the Rheumatic Diseases collection on glucocorticoids (2020-2023): novel insights and advances in therapy.
    Ann Rheum Dis. 2024;83:4-8.
    PubMed    


  31. BERRY JS, Tarn J, Casement J, Duret PM, et al
    Examining the biological pathways underlying clinical heterogeneity in Sjogren's syndrome: proteomic and network analysis.
    Ann Rheum Dis. 2024;83:88-95.
    PubMed     Abstract available


    December 2023
  32. AYMON R, Mongin D, Bergstra SA, Choquette D, et al
    Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).
    Ann Rheum Dis. 2023 Dec 8:ard-2023-224670. doi: 10.1136/ard-2023-224670.
    PubMed     Abstract available


  33. TRIAILLE C, Tilman G, Sokolova T, Loriot A, et al
    Disease activity drives transcriptomic heterogeneity in early untreated rheumatoid synovitis.
    Ann Rheum Dis. 2023;82:1538-1546.
    PubMed     Abstract available


  34. YAMADA H, Haraguchi A, Tsuru T, Kondo M, et al
    Low avidity observed for anti-citrullinated peptide antibody is not a general phenomenon for autoantibodies.
    Ann Rheum Dis. 2023;82:1637-1638.
    PubMed    


    November 2023
  35. LIEN HJT, Pedersen TT, Jakobsen B, Flatberg A, et al
    Single-cell resolution of longitudinal blood transcriptome profiles in rheumatoid arthritis, systemic lupus erythematosus and healthy control pregnancies.
    Ann Rheum Dis. 2023 Nov 30:ard-2023-224644. doi: 10.1136/ard-2023-224644.
    PubMed     Abstract available


  36. PERTSINIDOU E, Saevarsdottir S, Manivel VA, Klareskog L, et al
    In early rheumatoid arthritis, anticitrullinated peptide antibodies associate with low number of affected joints and rheumatoid factor associates with systemic inflammation.
    Ann Rheum Dis. 2023 Nov 27:ard-2023-224728. doi: 10.1136/ard-2023-224728.
    PubMed     Abstract available


  37. MOULIN D, Millard M, Taieb M, Michaudel C, et al
    Counteracting tryptophan metabolism alterations as a new therapeutic strategy for rheumatoid arthritis.
    Ann Rheum Dis. 2023 Nov 24:ard-2023-224014. doi: 10.1136/ard-2023-224014.
    PubMed     Abstract available


  38. GOLDMANN K, Spiliopoulou A, Iakovliev A, Plant D, et al
    Expression quantitative trait loci analysis in rheumatoid arthritis identifies tissue specific variants associated with severity and outcome.
    Ann Rheum Dis. 2023 Nov 18:ard-2023-224540. doi: 10.1136/ard-2023-224540.
    PubMed     Abstract available


  39. SIMON TA, Dong L, Suissa S, Michaud K, et al
    Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies.
    Ann Rheum Dis. 2023 Nov 6:ard-2023-224356. doi: 10.1136/ard-2023-224356.
    PubMed     Abstract available



  40. Correction: Cytokine-directed cellular cross-talk imprints synovial pathotypes in rheumatoid arthritis.
    Ann Rheum Dis. 2023;82:e227.
    PubMed    



  41. Correction: Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study.
    Ann Rheum Dis. 2023;82:e222.
    PubMed    


  42. WOLLHEIM FA
    Nanna Svartz (1890-1986) and the discovery of sulfasalazine.
    Ann Rheum Dis. 2023;82:1382-1386.
    PubMed    


  43. SAVIANO A, Manosour AA, Raucci F, Merlino F, et al
    New biologic (Ab-IPL-IL-17) for IL-17-mediated diseases: identification of the bioactive sequence (nIL-17) for IL-17A/F function.
    Ann Rheum Dis. 2023;82:1415-1428.
    PubMed     Abstract available


  44. SCHERLINGER M, Schaeverbeke T
    Correspondence on 'Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting'.
    Ann Rheum Dis. 2023;82:e221.
    PubMed    


    October 2023
  45. WESTHOVENS R, Verschueren P
    Lessons from negative phase 3 trials in rheumatoid arthritis anno 2023.
    Ann Rheum Dis. 2023 Oct 30:ard-2023-224904. doi: 10.1136/ard-2023-224904.
    PubMed    


  46. KONZETT V, Kerschbaumer A, Smolen JS, Kristianslund EK, et al
    Definition of rheumatoid arthritis flare based on SDAI and CDAI.
    Ann Rheum Dis. 2023 Oct 27:ard-2023-224742. doi: 10.1136/ard-2023-224742.
    PubMed     Abstract available


  47. VAN WESEMAEL TJ, Reijm S, Kawakami A, Dorjee AL, et al
    IgM antibodies against acetylated proteins as a possible starting point of the anti-modified protein antibody response in rheumatoid arthritis.
    Ann Rheum Dis. 2023 Oct 3:ard-2023-224553. doi: 10.1136/ard-2023-224553.
    PubMed    



  48. Correction: Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label randomised controlled ORAL Surveillance trial.
    Ann Rheum Dis. 2023;82:e219.
    PubMed    


  49. VAN MULLIGEN E, van der Helm-van Mil A, de Jong PHP
    Methotrexate prolongs TNF inhibitor survival, but only in autoantibody-positive rheumatoid arthritis: a validation study.
    Ann Rheum Dis. 2023;82:e217.
    PubMed    


  50. MA KS, Chiang CH, Chen YW, Wang LT, et al
    Correspondence to 'Bacterial citrullinated epitopes generated by Porphyromonas gingivalis infection-a missing link for ACPA production'.
    Ann Rheum Dis. 2023;82:e216.
    PubMed    


    September 2023
  51. KONZETT V, Kerschbaumer A, Smolen JS, Aletaha D, et al
    Determination of the most appropriate ACR response definition for contemporary drug approval trials in rheumatoid arthritis.
    Ann Rheum Dis. 2023 Sep 27:ard-2023-224477. doi: 10.1136/ard-2023-224477.
    PubMed     Abstract available


  52. FLEISCHMANN RM, van der Heijde D, Strand V, Atsumi T, et al
    Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).
    Ann Rheum Dis. 2023 Sep 12:ard-2023-224482. doi: 10.1136/ard-2023-224482.
    PubMed     Abstract available


  53. YAP CF, Nair N, de Vries A, Loeff FC, et al
    HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2023 Sep 12:ard-2023-223955. doi: 10.1136/ard-2023-223955.
    PubMed    


  54. TAYLOR PC, Weinblatt ME, McInnes IB, Atsumi T, et al
    Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3).
    Ann Rheum Dis. 2023 Sep 11:ard-2023-224449. doi: 10.1136/ard-2023-224449.
    PubMed     Abstract available



  55. News from EULAR.
    Ann Rheum Dis. 2023;82:1242.
    PubMed    


  56. LONGOBARDI S, Lopez-Davis C, Khatri B, Georgescu C, et al
    Autoantibodies identify primary Sjogren's syndrome in patients lacking serum IgG specific for Ro/SS-A and La/SS-B.
    Ann Rheum Dis. 2023;82:1181-1190.
    PubMed     Abstract available


  57. FERRI C, Giuggioli D, Raimondo V, Fallahi P, et al
    COVID-19 in Italian patients with rheumatic autoimmune systemic diseases.
    Ann Rheum Dis. 2023;82:e211.
    PubMed    


    August 2023
  58. VAN OUWERKERK L, Verschueren P, Boers M, Emery P, et al
    Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time?
    Ann Rheum Dis. 2023 Aug 22:ard-2023-224270. doi: 10.1136/ard-2023-224270.
    PubMed     Abstract available


  59. LILLEGRAVEN S, Paulshus Sundlisaeter N, Aga AB, Sexton J, et al
    Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial.
    Ann Rheum Dis. 2023 Aug 22:ard-2023-224476. doi: 10.1136/ard-2023-224476.
    PubMed     Abstract available


  60. ALMAYALI AAH, Boers M, Hartman L, Opris D, et al
    Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial.
    Ann Rheum Dis. 2023 Aug 4:ard-2023-223977. doi: 10.1136/ard-2023-223977.
    PubMed     Abstract available


  61. RUSSELL MD, Stovin C, Alveyn E, Adeyemi O, et al
    JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications.
    Ann Rheum Dis. 2023;82:1059-1067.
    PubMed     Abstract available


  62. BERGSTRA SA, Sepriano A, Chopra A, Winchow LL, et al
    Country-level socioeconomic status relates geographical latitude to the onset of RA: a worldwide cross-sectional analysis in the METEOR registry.
    Ann Rheum Dis. 2023;82:1018-1024.
    PubMed     Abstract available


  63. HUANG YT, Jenkins DA, Peek N, Dixon WG, et al
    High frequency of long-term opioid use among patients with rheumatic and musculoskeletal diseases initiating opioids for the first time.
    Ann Rheum Dis. 2023;82:1116-1117.
    PubMed    


  64. LEE S, Choi E, Chae S, Koh JH, et al
    Identification of MYH9 as a key regulator for synoviocyte migration and invasion through secretome profiling.
    Ann Rheum Dis. 2023;82:1035-1048.
    PubMed     Abstract available


  65. REINISCH W, Hellstrom W, Dolhain RJEM, Sikka S, et al
    Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies.
    Ann Rheum Dis. 2023;82:1049-1058.
    PubMed     Abstract available


  66. DALBETH N, Neogi T
    Where are the women 'Heroes and Pillars of Rheumatology'?
    Ann Rheum Dis. 2023;82:e199.
    PubMed    


    July 2023
  67. SO H, Lam TO, Meng H, Lam SHM, et al
    Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study.
    Ann Rheum Dis. 2023 Jul 24:ard-2023-224185. doi: 10.1136/ard-2023-224185.
    PubMed     Abstract available


  68. QIU YY, Neogi T, Muhammad LN, Song J, et al
    Anti-cyclic citrullinated peptide antibody and pain sensitisation in patients with rheumatoid arthritis: a cross-sectional analysis.
    Ann Rheum Dis. 2023 Jul 19:ard-2023-224492. doi: 10.1136/ard-2023-224492.
    PubMed    


  69. OZEN G, Pedro S, Michaud K
    Major adverse cardiovascular events and mortality with opioids versus NSAIDs initiation in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2023 Jul 17:ard-2023-224339. doi: 10.1136/ard-2023-224339.
    PubMed     Abstract available


  70. VAN ESVELD L, Cox JM, Kuijper TM, Bosch TM, et al
    Cost-utility analysis of tapering strategies of biologicals in rheumatoid arthritis patients in the Netherlands.
    Ann Rheum Dis. 2023 Jul 9:ard-2023-224190. doi: 10.1136/ard-2023-224190.
    PubMed     Abstract available


  71. OSTERGAARD M, van Vollenhoven RF, Rudin A, Hetland ML, et al
    Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial.
    Ann Rheum Dis. 2023 Jul 9:ard-2023-224116. doi: 10.1136/ard-2023-224116.
    PubMed     Abstract available


  72. KIMURA A, Takagi T, Thamamongood T, Sakamoto S, et al
    Extracellular aaRSs drive autoimmune and inflammatory responses in rheumatoid arthritis via the release of cytokines and PAD4.
    Ann Rheum Dis. 2023 Jul 2:ard-2023-224055. doi: 10.1136/ard-2023-224055.
    PubMed     Abstract available


  73. OSKAM N, Ooijevaar-De Heer P, Kos D, Jeremiasse J, et al
    Rheumatoid factor autoantibody repertoire profiling reveals distinct binding epitopes in health and autoimmunity.
    Ann Rheum Dis. 2023;82:945-956.
    PubMed     Abstract available


  74. BASS AR, Abdel-Wahab N, Reid PD, Sparks JA, et al
    Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis.
    Ann Rheum Dis. 2023;82:920-926.
    PubMed     Abstract available


  75. KRISTENSEN LE, Danese S, Yndestad A, Wang C, et al
    Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance.
    Ann Rheum Dis. 2023;82:901-910.
    PubMed     Abstract available


  76. YAZICI H, Yazici Y
    Correspondence on 'classification criteria: time for a rethink 'by D Porter et al'.
    Ann Rheum Dis. 2023;82:e176.
    PubMed    


  77. CACCIAPAGLIA F, Manfredi A, Erre G, Piga M, et al
    Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M et al. The impact of cardiovascular c
    Ann Rheum Dis. 2023;82:e159.
    PubMed    


    June 2023
  78. KUGLER M, Dellinger M, Kartnig F, Muller L, et al
    Cytokine-directed cellular cross-talk imprints synovial pathotypes in rheumatoid arthritis.
    Ann Rheum Dis. 2023 Jun 21:ard-2022-223396. doi: 10.1136/ard-2022-223396.
    PubMed     Abstract available


  79. FLEISCHMANN R, Curtis JR, Charles-Schoeman C, Mysler E, et al
    Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.
    Ann Rheum Dis. 2023 Jun 12:ard-2023-223916. doi: 10.1136/ard-2023-223916.
    PubMed     Abstract available



  80. News from EULAR.
    Ann Rheum Dis. 2023;82:886.
    PubMed    


  81. DE BENEDETTI F, Grom AA, Brogan PA, Bracaglia C, et al
    Efficacy and safety of emapalumab in macrophage activation syndrome.
    Ann Rheum Dis. 2023;82:857-865.
    PubMed     Abstract available


  82. STYRKARSDOTTIR U, Stefansdottir L, Thorleifsson G, Stefansson OA, et al
    Meta-analysis of erosive hand osteoarthritis identifies four common variants that associate with relatively large effect.
    Ann Rheum Dis. 2023;82:873-880.
    PubMed     Abstract available


  83. LI T, Ge C, Kramer A, Sareila O, et al
    Pathogenic antibody response to glucose-6-phosphate isomerase targets a modified epitope uniquely exposed on joint cartilage.
    Ann Rheum Dis. 2023;82:799-808.
    PubMed     Abstract available


  84. OSPELT C
    Site of invasion revisited: epigenetic drivers of joint destruction in RA.
    Ann Rheum Dis. 2023;82:734-739.
    PubMed     Abstract available


  85. ALETAHA D, Kerschbaumer A, Kastrati K, Dejaco C, et al
    Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.
    Ann Rheum Dis. 2023;82:773-787.
    PubMed     Abstract available


  86. FELTEN R, Gottenberg JE
    Response to: 'Correspondence on 'Interleukin 6 receptor inhibition in primary Sjogren syndrome: a multicentre double-blind randomised placebo-controlled trial'' by de Wolff et al.
    Ann Rheum Dis. 2023;82:e149.
    PubMed    


  87. DE WOLFF L, Arends S, Verstappen GM, Vissink A, et al
    Correspondence on 'Interleukin 6 receptor inhibition in primary Sjogren syndrome: a multicentre double-blind randomised controlled trial'.
    Ann Rheum Dis. 2023;82:e148.
    PubMed    


    May 2023
  88. TAKEUCHI T, Tanaka S, Murata M, Tanaka Y, et al
    Irreversible covalent Bruton's tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial.
    Ann Rheum Dis. 2023 May 22:ard-2022-223759. doi: 10.1136/ard-2022-223759.
    PubMed     Abstract available


  89. WINTHROP KL, Isaacs JD, Mease PJ, Boumpas DT, et al
    Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022.
    Ann Rheum Dis. 2023;82:594-598.
    PubMed     Abstract available


  90. BAKER JF, England BR, Mikuls TR
    Response to: 'Correspondence on 'Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis'' by Ruscitti et al.
    Ann Rheum Dis. 2023;82:e120.
    PubMed    


  91. RUSCITTI P, Sesti G, Cipriani P, Gerli R, et al
    Correspondence on 'Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis'.
    Ann Rheum Dis. 2023;82:e119.
    PubMed    


    April 2023
  92. BOERS M
    Correspondence on "Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?" by Studenic et al.
    Ann Rheum Dis. 2023 Apr 20:ard-2022-223599. doi: 10.1136/ard-2022-223599.
    PubMed    


  93. STUDENIC P, Aletaha D, Stamm TA, de Wit M, et al
    Response to: Correspondence on "Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?" by Studenic et al.
    Ann Rheum Dis. 2023 Apr 20:ard-2022-223627. doi: 10.1136/ard-2022-223627.
    PubMed    


  94. MEYER A, Sienes RE, Nijim W, Zanotti B, et al
    Syntenin-1-mediated arthritogenicity is advanced by reprogramming RA metabolic macrophages and Th1 cells.
    Ann Rheum Dis. 2023;82:483-495.
    PubMed     Abstract available


  95. REUTER K, Rocca E
    Correspondence on 'Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis'.
    Ann Rheum Dis. 2023;82:e91.
    PubMed    


  96. ZHENG BK
    Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'.
    Ann Rheum Dis. 2023;82:e93.
    PubMed    


  97. GEORGIADIS AN, Pelechas E, Voulgari PV, Drosos AA, et al
    Correspondence on 'Cardiovascular effects of biological versus csDMARD therapy in treatment naive, early rheumatoid arthritis'.
    Ann Rheum Dis. 2023;82:e89.
    PubMed    


  98. PLEIN S, Buch MH
    Response to: 'Correspondence on 'Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naive, early rheumatoid arthritis'' by Georgiadis et al.
    Ann Rheum Dis. 2023;82:e90.
    PubMed    


  99. ABTAHI S, Driessen JHM, Burden AM, Souverein PC, et al
    Response to: 'Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'' by Zheng.
    Ann Rheum Dis. 2023;82:e94.
    PubMed    


  100. ZERVOU MI, Goulielmos GN
    Correspondence on 'Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden'.
    Ann Rheum Dis. 2023;82:e87.
    PubMed    


  101. CONRAD N, McInnes IB, Mcmurray JJV, Sattar N, et al
    Patients with a range of rheumatic diseases are at increased risk of cardiovascular disorders towards a re-evaluation of the European League against Rheumatism (EULAR)'s recommendations for cardiovascular risk management?
    Ann Rheum Dis. 2023;82:457-459.
    PubMed    


  102. SHARMA C, Whittle S, Haghighi PD, Burstein F, et al
    Response to 'Correspondence on 'Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis'' by Reuter et al.
    Ann Rheum Dis. 2023;82:e92.
    PubMed    


  103. MOLANDER V, Askling J
    Response to: 'Correspondence on 'Risk of venous thromboembolism in rheumatoid arthritis and its association with disease activity: a nationwide cohort study from Sweden'' by Zervou et al.
    Ann Rheum Dis. 2023;82:e88.
    PubMed    


    March 2023
  104. YAMADA S, Nagafuchi Y, Wang M, Ota M, et al
    Immunomics analysis of rheumatoid arthritis identified precursor dendritic cells as a key cell subset of treatment resistance.
    Ann Rheum Dis. 2023 Mar 14:ard-2022-223645. doi: 10.1136/ard-2022-223645.
    PubMed     Abstract available


  105. HUSS V, Bower H, Hellgren K, Frisell T, et al
    Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.
    Ann Rheum Dis. 2023 Mar 3:ard-2022-223636. doi: 10.1136/ard-2022-223636.
    PubMed     Abstract available



  106. Correction: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
    Ann Rheum Dis. 2023;82:e76.
    PubMed    



  107. News from EULAR.
    Ann Rheum Dis. 2023;82:448.
    PubMed    


  108. LOPES AP, Hillen MR, Hinrichs AC, Blokland SL, et al
    Deciphering the role of cDC2s in Sjogren's syndrome: transcriptomic profile links altered antigen processes with IFN signature and autoimmunity.
    Ann Rheum Dis. 2023;82:374-383.
    PubMed     Abstract available


  109. WANG B, Chen S, Xuan J, Li Y, et al
    Correspondence on 'Interleukin 6 receptor inhibition in primary Sjogren syndrome: a multicentre double-blind randomised placebo-controlled trial'.
    Ann Rheum Dis. 2023;82:e67.
    PubMed    


  110. FELTEN R, Gottenberg JE
    Response to: 'Correspondence on 'Interleukin 6 receptor inhibition in primary Sjogren syndrome: a multicentre double-blind randomised placebo-controlled trial'' by Wang et al.
    Ann Rheum Dis. 2023;82:e68.
    PubMed    


  111. AYDIN SZ, Hepworth E, Tugwell P
    Correspondence on 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'.
    Ann Rheum Dis. 2023;82:e69.
    PubMed    


  112. FREITES NUNEZ DD, Leon L, Mucientes A, Rodriguez-Rodriguez L, et al
    Response to: 'Correspondence on 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'' by Aydin et al.
    Ann Rheum Dis. 2023;82:e70.
    PubMed    


  113. MOUTSOPOULOS HM
    Correspondence on 'Jan Gosta Waldenstrom and rheumatology'.
    Ann Rheum Dis. 2023;82:e59.
    PubMed    


  114. NOVELLA-NAVARRO M, Plasencia-Rodriguez C, Tornero C, Navarro-Compan V, et al
    Correspondence on: 'EULAR definition of difficult-to-treat rheumatoid arthritis'.
    Ann Rheum Dis. 2023;82:e55.
    PubMed    


  115. ROODENRIJS NMT, Welsing PMJ, van der Goes MC, Jacobs JW, et al
    Response to: 'Correspondence on 'EULAR definition of difficult-to-treat rheumatoid arthritis'' by Novella-Navarro et al.
    Ann Rheum Dis. 2023;82:e56.
    PubMed    


    February 2023
  116. SMITH SL, Alexander S, Nair N, Viatte S, et al
    Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis.
    Ann Rheum Dis. 2023 Feb 21:annrheumdis-2022-222519. doi: 10.1136/ard-2022-222519
    PubMed     Abstract available


  117. FRISELL T, Bower H, Morin M, Baecklund E, et al
    Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme.
    Ann Rheum Dis. 2023 Feb 14:ard-2022-223762. doi: 10.1136/ard-2022-223762.
    PubMed     Abstract available


  118. O'NEIL LJ, Oliveira CB, Wang X, Navarrete M, et al
    Neutrophil extracellular trap-associated carbamylation and histones trigger osteoclast formation in rheumatoid arthritis.
    Ann Rheum Dis. 2023 Feb 3:ard-2022-223568. doi: 10.1136/ard-2022-223568.
    PubMed     Abstract available



  119. Correction: Loss of balance between protective and pro-inflammatory synovial tissue T-cell polyfunctionality predates clinical onset of rheumatoid arthritis.
    Ann Rheum Dis. 2023;82:e53.
    PubMed    


  120. TARANNUM S, Widdifield J, Wu CF, Johnson SR, et al
    Understanding sex-related differences in healthcare utilisation among patients with inflammatory arthritis: a population-based study.
    Ann Rheum Dis. 2023;82:283-291.
    PubMed     Abstract available


  121. POMBO-SUAREZ M, Sanchez-Piedra C, Gomez-Reino J, Lauper K, et al
    After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries.
    Ann Rheum Dis. 2023;82:175-181.
    PubMed     Abstract available


  122. HOSONO Y, Sie B, Pinal-Fernandez I, Pak K, et al
    Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1gamma autoantibodies.
    Ann Rheum Dis. 2023;82:246-252.
    PubMed     Abstract available


  123. SUN T, Ni J
    Correspondence on 'Prevotella copri in individuals at risk for rheumatoid arthritis'.
    Ann Rheum Dis. 2023;82:e50.
    PubMed    


  124. GILBERT BTP, Finckh A, Alpizar Rodriguez D
    Response to: 'Correspondence on 'Prevotella copri in individuals at risk for rheumatoid arthritis'' by Sun and Ni.
    Ann Rheum Dis. 2023;82:e51.
    PubMed    


  125. DE COCK D, Soenen I, Bertrand D, Pazmino S, et al
    Correspondence on 'EULAR recommendations for a core data set for pregnancy registries in rheumatology'.
    Ann Rheum Dis. 2023;82:e44.
    PubMed    


  126. RUYSSEN-WITRAND A, Soubrier M, Basch A, Truchetet ME, et al
    Correspondence on 'Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort'.
    Ann Rheum Dis. 2023;82:e32.
    PubMed    


  127. CIUREA A, Finckh A
    Response to 'Correspondence on 'Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort' by Ruyssen-Witrand et al.
    Ann Rheum Dis. 2023;82:e33.
    PubMed    


    January 2023
  128. DOUGADOS M, Charles-Schoeman C, Szekanecz Z, Giles JT, et al
    Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme.
    Ann Rheum Dis. 2023 Jan 31:ard-2022-223406. doi: 10.1136/ard-2022-223406.
    PubMed    


  129. NII T, Maeda Y, Motooka D, Naito M, et al
    Genomic repertoires linked with pathogenic potency of arthritogenic Prevotella copri isolated from the gut of patients with rheumatoid arthritis.
    Ann Rheum Dis. 2023 Jan 10:annrheumdis-2022-222881. doi: 10.1136/ard-2022-222881
    PubMed     Abstract available


  130. KERSCHBAUMER A, Stimakovits NM, Smolen JS, Stefanova T, et al
    Influence of active versus placebo control on treatment responses in randomised controlled trials in rheumatoid arthritis.
    Ann Rheum Dis. 2023 Jan 10:ard-2022-223349. doi: 10.1136/ard-2022-223349.
    PubMed     Abstract available


  131. POPE JE, Fleischmann RM
    Jack pot! What can we learn about registries with respect to treatment cycling in rheumatoid arthritis?
    Ann Rheum Dis. 2023 Jan 6:ard-2022-223071. doi: 10.1136/ard-2022-223071.
    PubMed    


  132. GWINNUTT JM, Wieczorek M, Balanescu A, Bischoff-Ferrari HA, et al
    2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases.
    Ann Rheum Dis. 2023;82:48-56.
    PubMed     Abstract available


  133. VAN MULLIGEN E, de Jong PHP
    Response to: 'Correspondence on 'Tapering towards DMARD-free remission in rheumatoid arthritis' by Garcia et al.
    Ann Rheum Dis. 2023;82:e10.
    PubMed    


  134. GARCIA IE, Abud-Mendoza C
    Correspondence on 'Tapering towards DMARD-free remission in rheumatoid arthritis'.
    Ann Rheum Dis. 2023;82:e9.
    PubMed    


  135. JONG GP, Pan LF, Lin TK, Chen HY, et al
    Correspondence on 'Impact of rheumatoid arthritis on major cardiovascular events in patients with and without coronary artery disease'.
    Ann Rheum Dis. 2023;82:e11.
    PubMed    


  136. LOGSTRUP BB, Olesen KKW, Masic D, Gyldenkerne C, et al
    Response to 'Correspondence on 'Impact of rheumatoid arthritis on major cardiovascular events in patients with and without coronary artery disease" by Jong et al.
    Ann Rheum Dis. 2023;82:e12.
    PubMed    


  137. SCHULZE-KOOPS H, Skapenko A, Krause A, Krueger K, et al
    Correspondence to 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'.
    Ann Rheum Dis. 2023;82:e1.
    PubMed    


  138. FREITES NUNEZ DD, Leon L, Mucientes A, Rodriguez-Rodriguez L, et al
    Response to: 'Correspondence on 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'' by Schulze-Koops et al.
    Ann Rheum Dis. 2023;82:e2.
    PubMed    


    December 2022
  139. HEBING RC, Lin M, Bulatovic Calasan M, Muller IB, et al
    Pharmacokinetics of oral and subcutaneous methotrexate in red and white blood cells in patients with early rheumatoid arthritis: the methotrexate monitoring trial.
    Ann Rheum Dis. 2022 Dec 21:ard-2022-223398. doi: 10.1136/ard-2022-223398.
    PubMed     Abstract available


  140. VAN OUWERKERK L, Boers M, Emery P, de Jong PH, et al
    Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2022 Dec 16:ard-2022-223443. doi: 10.1136/ard-2022-223443.
    PubMed     Abstract available


  141. KRONZER VL, Sparks JA
    Occupational inhalants, genetics and the respiratory mucosal paradigm for ACPA-positive rheumatoid arthritis.
    Ann Rheum Dis. 2022 Dec 6:ard-2022-223286. doi: 10.1136/ard-2022-223286.
    PubMed    


  142. TANG B, Liu Q, Ilar A, Wiebert P, et al
    Occupational inhalable agents constitute major risk factors for rheumatoid arthritis, particularly in the context of genetic predisposition and smoking.
    Ann Rheum Dis. 2022 Dec 6:ard-2022-223134. doi: 10.1136/ard-2022-223134.
    PubMed     Abstract available


  143. CURTIS JR, Yamaoka K, Chen YH, Bhatt DL, et al
    Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.
    Ann Rheum Dis. 2022 Dec 5:annrheumdis-2022-222543. doi: 10.1136/ard-2022-222543.
    PubMed     Abstract available


  144. CALISKAN Y
    News from EULAR.
    Ann Rheum Dis. 2022;81:1767.
    PubMed    


  145. KAWANO Y, Patel NJ, Wang X, Cook CE, et al
    Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave.
    Ann Rheum Dis. 2022;81:1742-1749.
    PubMed     Abstract available


  146. PRINGLE S, Verstappen GM, Bootsma H, Kroese FGM, et al
    Role of interaction between B cells and epithelial cells in pSS.
    Ann Rheum Dis. 2022;81:e260.
    PubMed    


  147. RIVIERE E, Mariette X, Nocturne G
    Response to: 'Role of interaction between B cells and epithelial cells in pSS' by Pringle et al.
    Ann Rheum Dis. 2022;81:e261.
    PubMed    


  148. WU BY, Chan CH, Wei JC
    Correspondence to 'Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases'.
    Ann Rheum Dis. 2022;81:e243.
    PubMed    


  149. HE P, Zhu H, Wu LF, Deng FY, et al
    Response to 'Correspondence on 'Rheumatoid arthritis-associated DNA methylation sites in peripheral blood mononuclear cells'' by Wang and Niu.
    Ann Rheum Dis. 2022;81:e259.
    PubMed    


  150. WANG H, Niu L
    Correspondence on 'Rheumatoid arthritis-associated DNA methylation sites in peripheral blood mononuclear cells'.
    Ann Rheum Dis. 2022;81:e258.
    PubMed    


    November 2022
  151. SOLOMON DH, Giles JT, Liao KP, Ridker PM, et al
    Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis.
    Ann Rheum Dis. 2022 Nov 30:ard-2022-223302. doi: 10.1136/ard-2022-223302.
    PubMed     Abstract available


  152. BERGSTRA SA, Sepriano A, Kerschbaumer A, van der Heijde D, et al
    Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Ann Rheum Dis. 2022 Nov 21:ard-2022-223358. doi: 10.1136/ard-2022-223358.
    PubMed     Abstract available


  153. SEPRIANO A, Kerschbaumer A, Bergstra SA, Smolen JS, et al
    Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Ann Rheum Dis. 2022 Nov 14. pii: ard-2022-223357. doi: 10.1136/ard-2022-223357.
    PubMed     Abstract available


  154. KERSCHBAUMER A, Sepriano A, Bergstra SA, Smolen JS, et al
    Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Ann Rheum Dis. 2022 Nov 11. pii: ard-2022-223365. doi: 10.1136/ard-2022-223365.
    PubMed     Abstract available


  155. SMOLEN JS, Landewe RBM, Bergstra SA, Kerschbaumer A, et al
    EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
    Ann Rheum Dis. 2022 Nov 10. pii: ard-2022-223356. doi: 10.1136/ard-2022-223356.
    PubMed     Abstract available


  156. PAPPAS DA, St John G, Etzel CJ, Fiore S, et al
    Response to 'Correspondence on 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US
    Ann Rheum Dis. 2022;81:e225.
    PubMed    


  157. ZHENG W, Leong PY, Wei JC
    Correspondence to 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry stu
    Ann Rheum Dis. 2022;81:e224.
    PubMed    


  158. KEDOR C, Zernicke J, Feist E
    Response to: 'Correspondence on 'Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease'' by Muraviov and Muraviova.
    Ann Rheum Dis. 2022;81:e234.
    PubMed    


  159. RUSCITTI P, Stamm TA, Giacomelli R
    Response to: 'Correspondence on 'Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease'' by Muraviov and Muraviova.
    Ann Rheum Dis. 2022;81:e233.
    PubMed    


  160. MURAVIOV Y, Muraviova L
    Correspondence on 'Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease'.
    Ann Rheum Dis. 2022;81:e232.
    PubMed    


  161. RUSCITTI P, Bruno F, Berardicurti O, Acanfora C, et al
    Response to: 'Correspondence on 'Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences' by Ruscitti et al' by Ch
    Ann Rheum Dis. 2022;81:e221.
    PubMed    


    October 2022
  162. STUDENIC P, Aletaha D, de Wit M, Stamm TA, et al
    American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision.
    Ann Rheum Dis. 2022 Oct 24. pii: ard-2022-223413. doi: 10.1136/ard-2022-223413.
    PubMed     Abstract available


  163. ZHENG Z, Chang L, Mu J, Ni Q, et al
    Database of synovial T cell repertoire of rheumatoid arthritis patients identifies cross-reactive potential against pathogens including unencountered SARS-CoV-2.
    Ann Rheum Dis. 2022 Oct 19. pii: ard-2022-222763. doi: 10.1136/ard-2022-222763.
    PubMed    


  164. GESSL I, Hana CA, Deimel T, Durechova M, et al
    Tenderness and radiographic progression in rheumatoid arthritis and psoriatic arthritis.
    Ann Rheum Dis. 2022 Oct 19. pii: ard-2022-222787. doi: 10.1136/ard-2022-222787.
    PubMed     Abstract available


  165. TU J, Chen W, Fang Y, Han D, et al
    PU.1 promotes development of rheumatoid arthritis via repressing FLT3 in macrophages and fibroblast-like synoviocytes.
    Ann Rheum Dis. 2022 Oct 5. pii: ard-2022-222708. doi: 10.1136/ard-2022-222708.
    PubMed     Abstract available


  166. HOISNARD L, Pina Vegas L, Dray-Spira R, Weill A, et al
    Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study.
    Ann Rheum Dis. 2022 Oct 5. pii: ard-2022-222824. doi: 10.1136/ard-2022-222824.
    PubMed     Abstract available


  167. DOUMEN M, Pazmino S, Bertrand D, De Cock D, et al
    Longitudinal trajectories of fatigue in early RA: the role of inflammation, perceived disease impact and early treatment response.
    Ann Rheum Dis. 2022;81:1385-1391.
    PubMed     Abstract available


  168. YANG Y, He X, Yao M, Xing W, et al
    Response to: 'Correspondence to: 'Combination of human umbilical cord mesenchymal stem cell transplantation with IFN-gamma treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis'' by Ma et al.
    Ann Rheum Dis. 2022;81:e207.
    PubMed    


  169. MA KS, Wang LT, Tsai SY
    Correspondence to: 'Combination of human umbilical cord mesenchymal (stromal) stem cell transplantation with IFN-gamma treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis'.
    Ann Rheum Dis. 2022;81:e206.
    PubMed    


  170. VAN MULLIGEN E, de Jong PHP
    Response to: 'Tapering antirheumatic drugs in a resource-poor setting: real-world evidence' by Haroon et al.
    Ann Rheum Dis. 2022;81:e209.
    PubMed    


  171. HAROON M, Khan Z, Aamer M
    Tapering antirheumatic drugs in a resource-poor setting: real-world evidence.
    Ann Rheum Dis. 2022;81:e208.
    PubMed    


  172. ANSARIN K, Taghizadieh A, Safiri S, Malek Mahdavi A, et al
    COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs.
    Ann Rheum Dis. 2022;81:e190.
    PubMed    


    September 2022
  173. MOLANDER V, Bower H, Frisell T, Delcoigne B, et al
    Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis.
    Ann Rheum Dis. 2022 Sep 23. pii: ard-2022-223050. doi: 10.1136/ard-2022-223050.
    PubMed     Abstract available


  174. CHARLES-SCHOEMAN C, Buch MH, Dougados M, Bhatt DL, et al
    Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
    Ann Rheum Dis. 2022 Sep 22. pii: ard-2022-222259. doi: 10.1136/ard-2022-222259.
    PubMed     Abstract available


  175. FEIST E, Fatenejad S, Grishin S, Korneva E, et al
    Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled
    Ann Rheum Dis. 2022 Sep 15. pii: ard-2022-222630. doi: 10.1136/ard-2022-222630.
    PubMed     Abstract available


    August 2022
  176. CHENG M, Zhao Y, Cui Y, Zhong C, et al
    Stage-specific roles of microbial dysbiosis and metabolic disorders in rheumatoid arthritis.
    Ann Rheum Dis. 2022 Aug 19. pii: ard-2022-222871. doi: 10.1136/ard-2022-222871.
    PubMed     Abstract available


  177. BALANESCU AR, Citera G, Pascual-Ramos V, Bhatt DL, et al
    Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial.
    Ann Rheum Dis. 2022 Aug 3. pii: ard-2022-222405. doi: 10.1136/ard-2022-222405.
    PubMed     Abstract available


  178. HUGLE T
    Learning from chess engines: how reinforcement learning could redefine clinical decision-making in rheumatology.
    Ann Rheum Dis. 2022;81:1072-1075.
    PubMed    


  179. CARDENAS-DE LA GARZA JA, Arvizu-Rivera RI, Galarza-Delgado DA
    Should patients starting biologics be screened for COVID-19?
    Ann Rheum Dis. 2022;81:e150.
    PubMed    


    July 2022
  180. SMEELE HTW, Roder E, Mulders AGMGJ, Steegers EAP, et al
    Tumour necrosis factor inhibitor use during pregnancy is associated with increased birth weight of rheumatoid arthritis patients' offspring.
    Ann Rheum Dis. 2022 Jul 11. pii: ard-2022-222679. doi: 10.1136/ard-2022-222679.
    PubMed     Abstract available


  181. SEROR R, Baron G, Camus M, Cornec D, et al
    Development and preliminary validation of the Sjogren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjogren's syndrome.
    Ann Rheum Dis. 2022;81:979-989.
    PubMed     Abstract available


  182. BAI W, Liu H, Dou L, Yang Y, et al
    Pilot study of baricitinib for active Sjogren's syndrome.
    Ann Rheum Dis. 2022;81:1050-1052.
    PubMed    


  183. VAN DER MEULEN TA, Vissink A, Bootsma H, Spijkervet FKL, et al
    Microbiome in Sjogren's syndrome: here we are.
    Ann Rheum Dis. 2022;81:e114.
    PubMed    


  184. MANASSON J, Blank RB, Scher JU
    Response to: 'Microbiome in Sjogren's syndrome: here we are' by van der Meulen et al.
    Ann Rheum Dis. 2022;81:e115.
    PubMed    


    June 2022
  185. QIN Y, Cai ML, Jin HZ, Huang W, et al
    Age-associated B cells contribute to the pathogenesis of rheumatoid arthritis by inducing activation of fibroblast-like synoviocytes via TNF-alpha-mediated ERK1/2 and JAK-STAT1 pathways.
    Ann Rheum Dis. 2022 Jun 27. pii: ard-2022-222605. doi: 10.1136/ard-2022-222605.
    PubMed     Abstract available


  186. KERSCHBAUMER A, Rivai ZI, Smolen JS, Aletaha D, et al
    Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis.
    Ann Rheum Dis. 2022 Jun 20. pii: annrheumdis-2021-221807.
    PubMed     Abstract available


  187. NEMETH T, Nagy G, Pap T
    Synovial fibroblasts as potential drug targets in rheumatoid arthritis, where do we stand and where shall we go?
    Ann Rheum Dis. 2022 Jun 17. pii: annrheumdis-2021-222021.
    PubMed     Abstract available


  188. LAUPER K, Ludici M, Mongin D, Bergstra SA, et al
    Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration.
    Ann Rheum Dis. 2022 Jun 15. pii: annrheumdis-2022-222586.
    PubMed     Abstract available


  189. VISMAN IM, Boers M, Vedder D, Twisk JW, et al
    Routine treatment of rheumatoid arthritis with biologics and targeted agents: changes in patients and their response over 15 years.
    Ann Rheum Dis. 2022 Jun 14. pii: annrheumdis-2022-222207.
    PubMed    


  190. COOLES FAH, Tarn J, Lendrem DW, Naamane N, et al
    Interferon-alpha-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming.
    Ann Rheum Dis. 2022 Jun 9. pii: annrheumdis-2022-222370.
    PubMed     Abstract available


  191. KVIEN TK
    EULAR 75-year anniversary: commentaries on key ARD papers from 1947.
    Ann Rheum Dis. 2022;81:751-752.
    PubMed    


  192. DELCOIGNE B, Ljung L, Provan SA, Glintborg B, et al
    Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries.
    Ann Rheum Dis. 2022;81:789-797.
    PubMed     Abstract available


  193. DROSOS GC, Vedder D, Houben E, Boekel L, et al
    EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.
    Ann Rheum Dis. 2022;81:768-779.
    PubMed     Abstract available


  194. RUSCITTI P, Stamm TA, Giacomelli R
    Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease.
    Ann Rheum Dis. 2022;81:e103.
    PubMed    


  195. KEDOR C, Listing J, Zernicke J, Feist E, et al
    Response to: 'Changing the outcome measures, changing the results? The urgent need of a specific Disease Activity Score to adult-onset Still's disease' by Ruscitti et al.
    Ann Rheum Dis. 2022;81:e104.
    PubMed    


  196. MINOIA F, Ravelli A
    Response to: 'Comparison of MS score and HScore for the diagnosis of adult-onset Still's disease associated macrophage activation syndrome' by Zhang et al.
    Ann Rheum Dis. 2022;81:e100.
    PubMed    


  197. ZHANG L, Yang X, Li TF, Liu X, et al
    Comparison of MS score and HScore for the diagnosis of adult-onset Still's disease-associated macrophage activation syndrome.
    Ann Rheum Dis. 2022;81:e99.
    PubMed    


    May 2022
  198. BOERS M, Hartman L, Opris-Belinski D, Bos R, et al
    Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial.
    Ann Rheum Dis. 2022 May 31. pii: annrheumdis-2021-221957.
    PubMed     Abstract available


  199. DAIEN C, Krogulec M, Gineste P, Steens JM, et al
    Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFalpha therapy: a placebo-controlled phase II study.
    Ann Rheum Dis. 2022 May 31. pii: annrheumdis-2022-222228.
    PubMed     Abstract available


  200. BUGATTI S, De Stefano L, D'Onofrio B, Nicrosini A, et al
    Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2022 May 27. pii: annrheumdis-2022-222436.
    PubMed     Abstract available


  201. ROUDIER J
    Correspondence on "Isolation of HLA-DR-naturally presented peptides identifies T-cell epitopes for rheumatoid arthritis" by Maggi et al.
    Ann Rheum Dis. 2022 May 20. pii: annrheumdis-2022-222750.
    PubMed    


  202. ROSENBAUM JT, Gill T, Martin TM, Friedman M, et al
    Marking the 50th anniversary of a seminal paper in rheumatology: did Baruj Benacerraf and Hugh McDevitt get it right?
    Ann Rheum Dis. 2022;81:618-621.
    PubMed    


  203. BROEREN MGA, Wang JJ, Balzaretti G, Groenen PJTA, et al
    Proteogenomic analysis of the autoreactive B cell repertoire in blood and tissues of patients with Sjogren's syndrome.
    Ann Rheum Dis. 2022;81:644-652.
    PubMed     Abstract available


  204. BUCH MH, Maksymowych WP, Boers M
    Managing the selection of placebo group switched to experimental treatment group in post-randomised controlled trial extension studies.
    Ann Rheum Dis. 2022;81:741-742.
    PubMed    


    April 2022
  205. DE STEFANO L, D'Onofrio B, Sakellariou G, Manzo A, et al
    Progressive increase in time to referral and persistently severe clinical presentation over the years in autoantibody-negative patients with rheumatoid arthritis in the setting of an early arthritis clinic.
    Ann Rheum Dis. 2022 Apr 29. pii: annrheumdis-2022-222264.
    PubMed    


  206. VAN OUWERKERK L, Palmowski A, Nevins IS, Buttgereit F, et al
    Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2022 Apr 25. pii: annrheumdis-2022-222338.
    PubMed     Abstract available


  207. SAEVARSDOTTIR S, Stefansdottir L, Sulem P, Thorleifsson G, et al
    Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset.
    Ann Rheum Dis. 2022 Apr 25. pii: annrheumdis-2021-221754.
    PubMed     Abstract available


  208. REIJM S, Brehler AS, Rantapaa-Dahlqvist S, Kawakami A, et al
    Cross-reactivity of anti-modified protein antibodies is also present in predisease and individuals without rheumatoid arthritis.
    Ann Rheum Dis. 2022 Apr 22. pii: annrheumdis-2022-222326.
    PubMed    


  209. MAGGI J, Carrascal M, Soto L, Neira O, et al
    Isolation of HLA-DR-naturally presented peptides identifies T-cell epitopes for rheumatoid arthritis.
    Ann Rheum Dis. 2022 Apr 22. pii: annrheumdis-2021-220371.
    PubMed     Abstract available


  210. VAN LINT JA, van Hunsel FPAM, Tas SW, Vonkeman HE, et al
    Hypoglycaemia following JAK inhibitor treatment in patients with diabetes.
    Ann Rheum Dis. 2022;81:597-599.
    PubMed    


  211. SAPER VE, Chen G, Guillerman RP, Khatri P, et al
    Response to: 'Successful treatment of plasma exchange for refractory systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome and severe lung disease' by Sato et al.
    Ann Rheum Dis. 2022;81:e62.
    PubMed    


  212. STUDENIC P, Felson DT, de Wit M, Smolen JS, et al
    Response to: 'Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis' by Bugatti et al.
    Ann Rheum Dis. 2022;81:e56.
    PubMed    


    March 2022
  213. VERSTAPPEN M, Huizinga TW, van der Helm-van Mil AH
    No excess mortality in contemporary undifferentiated arthritis, in contrast to rheumatoid arthritis: a study with a follow-up of at least 10 years.
    Ann Rheum Dis. 2022 Mar 2. pii: annrheumdis-2022-222145.
    PubMed    


  214. BOWER H, Frisell T, Di Giuseppe D, Delcoigne B, et al
    Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?
    Ann Rheum Dis. 2022;81:433-439.
    PubMed     Abstract available


  215. LIU D, Zhang F, Cao H, Wang X, et al
    Can sexual dimorphism in rheumatoid arthritis be attributed to the different abundance of Gardnerella?
    Ann Rheum Dis. 2022;81:e36.
    PubMed    


  216. YAMAMOTO M, Yoshikawa N, Tanaka H
    Efficacy of dupilumab reveals therapeutic target for IgG4-related disease: simultaneous control of inflammation and fibrosis.
    Ann Rheum Dis. 2022;81:e50.
    PubMed    


  217. REGUEIRO C, Gonzalez A
    Questions on 'Sequencing of the MHC region defines HLA-DQA1 as the major genetic risk for seropositive rheumatoid arthritis in Han Chinese population' by Guo et al.
    Ann Rheum Dis. 2022;81:e38.
    PubMed    


  218. MARTINSSON K, Durholz K, Schett G, Zaiss MM, et al
    Higher serum levels of short-chain fatty acids are associated with non-progression to arthritis in individuals at increased risk of RA.
    Ann Rheum Dis. 2022;81:445-447.
    PubMed    


  219. SAPER VE, Ombrello MJ, Tremoulet AH, Montero-Martin G, et al
    Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles.
    Ann Rheum Dis. 2022;81:406-415.
    PubMed     Abstract available


  220. GHALANDARI N, Kemper E, Crijns IH, Wolbink G, et al
    Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy.
    Ann Rheum Dis. 2022;81:402-405.
    PubMed     Abstract available


    February 2022
  221. ARAUJO CSR, Medeiros-Ribeiro AC, Saad CGS, Bonfiglioli KR, et al
    Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial.
    Ann Rheum Dis. 2022 Feb 22. pii: annrheumdis-2021-221916.
    PubMed     Abstract available


  222. LOPEZ-ROMERO P, de la Torre I, Haladyj E, Aletaha D, et al
    Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2022 Feb 22. pii: annrheumdis-2021-221323.
    PubMed     Abstract available


  223. FELSON D, Lacaille D, LaValley MP, Aletaha D, et al
    Response to: Correspondence on 'Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment' by Felson et al.
    Ann Rheum Dis. 2022 Feb 17. pii: annrheumdis-2021-221941.
    PubMed    


  224. FERREIRA RJO, Welsing PMJ, Jacobs JW, Gossec L, et al
    Correspondence on 'Re-examining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C reactive protein level and patient global assessment' by Felson et al.
    Ann Rheum Dis. 2022 Feb 17. pii: annrheumdis-2021-221917.
    PubMed    


  225. JIN S, Jiang N, Huo Y, Duan X, et al
    Management of rheumatoid arthritis in China: a study of the implementation of 2019 EULAR recommendations.
    Ann Rheum Dis. 2022 Feb 15. pii: annrheumdis-2021-221841.
    PubMed    


  226. TEDESCHI SK, Stratton J, Ellrodt JE, Whelan MG, et al
    Rheumatoid arthritis disease activity assessed by patient-reported outcomes and flow cytometry before and after an additional dose of COVID-19 vaccine.
    Ann Rheum Dis. 2022 Feb 15. pii: annrheumdis-2022-222232.
    PubMed    


  227. MEDEIROS-RIBEIRO AC, Bonfiglioli KR, Domiciano DS, Shimabuco AY, et al
    Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis.
    Ann Rheum Dis. 2022 Feb 8. pii: annrheumdis-2021-221735.
    PubMed     Abstract available


  228. SYMONS RA, Colella F, Collins FL, Rafipay AJ, et al
    Targeting the IL-6-Yap-Snail signalling axis in synovial fibroblasts ameliorates inflammatory arthritis.
    Ann Rheum Dis. 2022;81:214-224.
    PubMed     Abstract available


  229. VAN DER HELM-VAN MIL A, Landewe RB
    Response to: 'The cost of arthralgia 'pretreatment' to prevent rheumatoid arthritis' by Rothschild.
    Ann Rheum Dis. 2022;81:e19.
    PubMed    


  230. ROTHSCHILD BM
    The cost of arthralgia 'pretreatment' to prevent rheumatoid arthritis.
    Ann Rheum Dis. 2022;81:e18.
    PubMed    


    January 2022
  231. KHOSROW-KHAVAR F, Kim SC, Lee H, Lee SB, et al
    Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study.
    Ann Rheum Dis. 2022 Jan 13. pii: annrheumdis-2021-221915.
    PubMed     Abstract available


  232. GE C, Weisse S, Xu B, Dobritzsch D, et al
    Key interactions in the trimolecular complex consisting of the rheumatoid arthritis-associated DRB1*04:01 molecule, the major glycosylated collagen II peptide and the T-cell receptor.
    Ann Rheum Dis. 2022 Jan 13. pii: annrheumdis-2021-220500.
    PubMed     Abstract available



  233. Correction: Parsing multiomics landscape of activated synovial fibroblasts highlights drug targets linked to genetic risk of rheumatoid arthritis.
    Ann Rheum Dis. 2022;81:e17.
    PubMed    


  234. LEE YH
    Causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study.
    Ann Rheum Dis. 2022;81:e3.
    PubMed    


  235. INAMO J
    Response to: 'Causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study' by Lee.
    Ann Rheum Dis. 2022;81:e4.
    PubMed    


  236. KISSEL T, van Wesemael TJ, Lundquist A, Kokkonen H, et al
    Genetic predisposition (HLA-SE) is associated with ACPA-IgG variable domain glycosylation in the predisease phase of RA.
    Ann Rheum Dis. 2022;81:141-143.
    PubMed    


    December 2021
  237. BUGATTI S, De Stefano L, Balduzzi S, Greco MI, et al
    Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis.
    Ann Rheum Dis. 2021;80:1635-1638.
    PubMed    


  238. ROSENZWAJG M, Lorenzon R, Klatzmann D
    Response to: 'Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors' by Meyer et al.
    Ann Rheum Dis. 2021;80:e197.
    PubMed    


  239. MEYER A, Wittekind PS, Kotschenreuther K, Schiller J, et al
    Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors.
    Ann Rheum Dis. 2021;80:e196.
    PubMed    


  240. PEREZ-GARCIA LF, Roder E, Goekoop RJ, Hazes JMW, et al
    Impaired fertility in men diagnosed with inflammatory arthritis: results of a large multicentre study (iFAME-Fertility).
    Ann Rheum Dis. 2021;80:1545-1552.
    PubMed     Abstract available


  241. GRAALMANN T, Borst K, Manchanda H, Vaas L, et al
    B cell depletion impairs vaccination-induced CD8(+) T cell responses in a type I interferon-dependent manner.
    Ann Rheum Dis. 2021;80:1537-1544.
    PubMed     Abstract available


    November 2021
  242. SIMADER E, Tobudic S, Mandl P, Haslacher H, et al
    Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis.
    Ann Rheum Dis. 2021 Nov 29. pii: annrheumdis-2021-221347.
    PubMed     Abstract available


  243. BALSA A, Garcia de Yebenes MJ, Carmona L
    Multilevel factors predict medication adherence in rheumatoid arthritis: a 6-month cohort study.
    Ann Rheum Dis. 2021 Nov 29. pii: annrheumdis-2021-221163.
    PubMed     Abstract available


  244. FELSON D, Lacaille D, LaValley MP, Aletaha D, et al
    Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment.
    Ann Rheum Dis. 2021 Nov 16. pii: annrheumdis-2021-221653.
    PubMed    


  245. SIDDLE HJ, Chapman LS, Mankia K, Zabalan C, et al
    Perceptions and experiences of individuals at-risk of rheumatoid arthritis (RA) knowing about their risk of developing RA and being offered preventive treatment: systematic review and thematic synthesis of qualitative studies.
    Ann Rheum Dis. 2021 Nov 8. pii: annrheumdis-2021-221160.
    PubMed     Abstract available


  246. WINTHROP KL, Tanaka Y, Takeuchi T, Kivitz A, et al
    Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years.
    Ann Rheum Dis. 2021 Nov 5. pii: annrheumdis-2021-221051.
    PubMed     Abstract available


  247. TANAKA Y, Oba K, Takeuchi T
    Response to: 'Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al' by Berkhout et al.
    Ann Rheum Dis. 2021;80:e173.
    PubMed    


  248. BERKHOUT LC, l'Ami MJ, Wolbink GJ, Rispens T, et al
    Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al.
    Ann Rheum Dis. 2021;80:e172.
    PubMed    


  249. CHEN MH, Lee IC, Chen MH, Hou MC, et al
    Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease.
    Ann Rheum Dis. 2021;80:1393-1399.
    PubMed     Abstract available


  250. NABI H, Georgiadis S, Loft AG, Hendricks O, et al
    Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
    Ann Rheum Dis. 2021;80:1400-1409.
    PubMed     Abstract available


    October 2021
  251. TAYLOR PC, Takeuchi T, Burmester GR, Durez P, et al
    Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
    Ann Rheum Dis. 2021 Oct 27. pii: annrheumdis-2021-221276.
    PubMed     Abstract available


  252. LI X, Tong X, Yeung WWY, Kuan P, et al
    Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong.
    Ann Rheum Dis. 2021 Oct 22. pii: annrheumdis-2021-221571.
    PubMed     Abstract available


  253. CHRISTENSEN IE, Lillegraven S, Mielnik P, Bakland G, et al
    Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study.
    Ann Rheum Dis. 2021 Oct 8. pii: annrheumdis-2021-221007.
    PubMed     Abstract available


  254. IBANEZ-COSTA A, Perez-Sanchez C, Patino-Trives AM, Luque-Tevar M, et al
    Splicing machinery is impaired in rheumatoid arthritis, associated with disease activity and modulated by anti-TNF therapy.
    Ann Rheum Dis. 2021 Oct 8. pii: annrheumdis-2021-220308.
    PubMed     Abstract available


  255. WINTHROP KL, Nash P, Yamaoka K, Mysler E, et al
    Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials.
    Ann Rheum Dis. 2021 Oct 6. pii: annrheumdis-2021-220822.
    PubMed     Abstract available


  256. CAPELUSNIK D, Aletaha D
    Baseline predictors of different types of treatment success in rheumatoid arthritis.
    Ann Rheum Dis. 2021 Oct 4. pii: annrheumdis-2021-220853.
    PubMed     Abstract available


  257. FLOUDAS A, Neto N, Orr C, Canavan M, et al
    Loss of balance between protective and pro-inflammatory synovial tissue T-cell polyfunctionality predates clinical onset of rheumatoid arthritis.
    Ann Rheum Dis. 2021 Oct 1. pii: annrheumdis-2021-220458.
    PubMed     Abstract available


  258. MEEHAN GR, Thomas R, Al Khabouri S, Wehr P, et al
    Preclinical models of arthritis for studying immunotherapy and immune tolerance.
    Ann Rheum Dis. 2021;80:1268-1277.
    PubMed     Abstract available


  259. NIKIPHOROU E, Santos EJF, Marques A, Bohm P, et al
    2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis.
    Ann Rheum Dis. 2021;80:1278-1285.
    PubMed     Abstract available


    September 2021
  260. YOSHII I, Sawada N, Chijiwa T, Kokei S, et al
    Impact of sustaining SDAI remission for preventing incident of bone fragility fracture in patient with rheumatoid arthritis.
    Ann Rheum Dis. 2021 Sep 11. pii: annrheumdis-2021-221093.
    PubMed    


  261. MINOIA F, Ravelli A
    Response to 'Application of MS score in macrophage activation syndrome patients associated with adult onset Still's disease' by Wang et al.
    Ann Rheum Dis. 2021;80:e146.
    PubMed    


  262. WANG R, Li T, Ye S, Tan W, et al
    Application of MS score in macrophage activation syndrome patients associated with adult onset Still's disease.
    Ann Rheum Dis. 2021;80:e145.
    PubMed    


  263. OZEN G, Michaud K
    Response to: 'Medications associated with fracture risk in patients with rheumatoid arthritis' by Chen et al.
    Ann Rheum Dis. 2021;80:e141.
    PubMed    


  264. JONSSON R
    Henrik Sjogren (1899-1986): the syndrome and his legacy.
    Ann Rheum Dis. 2021;80:1108-1109.
    PubMed    


  265. MAASSEN JM, Dos Santos Sobrin R, Bergstra SA, Goekoop R, et al
    Glucocorticoid discontinuation in patients with early rheumatoid and undifferentiated arthritis: a post-hoc analysis of the BeSt and IMPROVED studies.
    Ann Rheum Dis. 2021;80:1124-1129.
    PubMed     Abstract available


  266. LIOU YS, Lin TK, Chen HY, Jong GP, et al
    Medications associated with fracture risk in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2021;80:e140.
    PubMed    


    August 2021
  267. HECKERT SL, Bergstra SA, Matthijssen XME, Goekoop-Ruiterman YPM, et al
    Joint inflammation tends to recur in the same joints during the rheumatoid arthritis disease course.
    Ann Rheum Dis. 2021 Aug 30. pii: annrheumdis-2021-220882.
    PubMed     Abstract available


  268. WANG Y, Xie X, Zhang C, Su M, et al
    Rheumatoid arthritis, systemic lupus erythematosus and primary Sjogren's syndrome shared megakaryocyte expansion in peripheral blood.
    Ann Rheum Dis. 2021 Aug 30. pii: annrheumdis-2021-220066.
    PubMed     Abstract available


  269. WALLACE ZS, Sparks JA, Robinson PC, Machado PM, et al
    Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks et al.
    Ann Rheum Dis. 2021 Aug 23. pii: annrheumdis-2021-220960.
    PubMed    


  270. GREMESE E, Ferraccioli G
    Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry" by Sparks et al.
    Ann Rheum Dis. 2021 Aug 23. pii: annrheumdis-2021-220932.
    PubMed    


  271. NAGY G, Roodenrijs NMT, Welsing PMJ, Kedves M, et al
    EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis.
    Ann Rheum Dis. 2021 Aug 18. pii: annrheumdis-2021-220973.
    PubMed     Abstract available


  272. VAN VOLLENHOVEN RF, Tas SW, Nurmohamed MT
    Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry" by Sparks et al.
    Ann Rheum Dis. 2021 Aug 13. pii: annrheumdis-2021-221146.
    PubMed    


  273. HOLTEN K, Paulshus Sundlisater N, Lillegraven S, Sexton J, et al
    Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment.
    Ann Rheum Dis. 2021 Aug 13. pii: annrheumdis-2021-220750.
    PubMed     Abstract available


  274. SPARKS JA, Wallace ZS, Seet AM, Robinson PC, et al
    Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks et al.
    Ann Rheum Dis. 2021 Aug 13. pii: annrheumdis-2021-221157.
    PubMed    


  275. PLATZER A, Alasti F, Smolen JS, Aletaha D, et al
    Trajectory clusters of radiographic progression in patients with rheumatoid arthritis: associations with clinical variables.
    Ann Rheum Dis. 2021 Aug 10. pii: annrheumdis-2021-220331.
    PubMed     Abstract available


  276. MANKIA K, Siddle HJ, Kerschbaumer A, Alpizar Rodriguez D, et al
    EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis.
    Ann Rheum Dis. 2021 Aug 6. pii: annrheumdis-2021-220884.
    PubMed     Abstract available


  277. NASONOV E, Fatenejad S, Feist E, Ivanova M, et al
    Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study.
    Ann Rheum Dis. 2021 Aug 3. pii: annrheumdis-2021-219876.
    PubMed     Abstract available


  278. SPARKS JA
    Towards clinical significance of the MUC5B promoter variant and risk of rheumatoid arthritis-associated interstitial lung disease.
    Ann Rheum Dis. 2021 Aug 3. pii: annrheumdis-2021-220856.
    PubMed    


  279. PALOMAKI A, Palotie A, Koskela J, Eklund KK, et al
    Lifetime risk of rheumatoid arthritis-associated interstitial lung disease in MUC5B mutation carriers.
    Ann Rheum Dis. 2021 Aug 3. pii: annrheumdis-2021-220698.
    PubMed     Abstract available


  280. VALLEJO-YAGUE E, Keystone EC, Kandhasamy S, Micheroli R, et al
    Primary and secondary non-response: in need of operational definitions in observational studies.
    Ann Rheum Dis. 2021;80:961-964.
    PubMed    


  281. NAKAMURA H, Tanaka T, Pranzatelli T, Ji Y, et al
    Lysosome-associated membrane protein 3 misexpression in salivary glands induces a Sjogren's syndrome-like phenotype in mice.
    Ann Rheum Dis. 2021;80:1031-1039.
    PubMed     Abstract available


  282. WANG H, Stewart S, Darlow B, Horgan B, et al
    Patient research partner involvement in rheumatology clinical trials: analysis of journal articles 2016-2020.
    Ann Rheum Dis. 2021;80:1095-1096.
    PubMed    


  283. BOWER H, Frisell T, Di Giuseppe D, Delcoigne B, et al
    Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study.
    Ann Rheum Dis. 2021;80:1086-1093.
    PubMed     Abstract available


  284. MATTHIJSSEN XME, Wouters F, Sidhu N, Niemantsverdriet E, et al
    Tenosynovitis has a high sensitivity for early ACPA-positive and ACPA-negative RA: a large cross-sectional MRI study.
    Ann Rheum Dis. 2021;80:974-980.
    PubMed     Abstract available


  285. ASSAN F, Seror R, Mariette X, Nocturne G, et al
    New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS.
    Ann Rheum Dis. 2021;80:e122.
    PubMed    


    July 2021
  286. REDEKER I, Albrecht K, Kekow J, Burmester GR, et al
    Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register.
    Ann Rheum Dis. 2021 Jul 28. pii: annrheumdis-2021-220651.
    PubMed     Abstract available


  287. WOUTERS F, Maurits MP, van Boheemen L, Verstappen M, et al
    Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis.
    Ann Rheum Dis. 2021 Jul 20. pii: annrheumdis-2021-220546.
    PubMed     Abstract available



  288. Retraction: Dominant B cell receptor clones in peripheral blood predict onset of arthritis in individuals at risk for rheumatoid arthritis.
    Ann Rheum Dis. 2021 Jul 6. pii: annrheumdis-2017-211351.
    PubMed    


  289. DUMOULIN QA, Matthijssen XME, Wouters F, Krijbolder DI, et al
    Correspondence on 'Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis'.
    Ann Rheum Dis. 2021 Jul 5. pii: annrheumdis-2021-220511.
    PubMed    


  290. GESSL I, Aletaha D, Mandl P
    Response to: 'Correspondence on 'Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis'' by Dumoulin et al.
    Ann Rheum Dis. 2021 Jul 5. pii: annrheumdis-2021-220922.
    PubMed    


  291. OCON AJ, Reed G, Pappas DA, Curtis JR, et al
    Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis.
    Ann Rheum Dis. 2021 Jul 2. pii: annrheumdis-2021-220577.
    PubMed     Abstract available


  292. WONG AY, MacKenna B, Morton CE, Schultze A, et al
    Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts.
    Ann Rheum Dis. 2021;80:943-951.
    PubMed     Abstract available


  293. JOUSSE-JOULIN S, D'Agostino MA, Hocevar A, Naredo E, et al
    Response to: 'Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren's syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren's sy
    Ann Rheum Dis. 2021;80:e112.
    PubMed    


  294. LAI SW, Kuo YH, Liao KF
    Chronic hydroxychloroquine exposure and the risk of Alzheimer's disease.
    Ann Rheum Dis. 2021;80:e105.
    PubMed    


  295. COIFFIER G, Martel A, Albert JD, Lescoat A, et al
    Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren's syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren's syndrome?
    Ann Rheum Dis. 2021;80:e111.
    PubMed    


  296. TRAVES PG, Murray B, Campigotto F, Galien R, et al
    JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
    Ann Rheum Dis. 2021;80:865-875.
    PubMed     Abstract available


    June 2021
  297. JAIN S, Dhir V
    Correspondence on 'Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial'.
    Ann Rheum Dis. 2021 Jun 30. pii: annrheumdis-2021-220816.
    PubMed    


  298. STOUTEN V, Westhovens R, Pazmino S, De Cock D, et al
    Response to: 'Correspondence on 'Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial'' by Jain and Dhir et al.
    Ann Rheum Dis. 2021 Jun 30. pii: annrheumdis-2021-220857.
    PubMed    


  299. ALBACH FN, Burmester GR, Biesen R
    Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response.
    Ann Rheum Dis. 2021 Jun 24. pii: annrheumdis-2021-220834.
    PubMed    


  300. SHIPA MRA, Amarnani R, Yeoh SA, Mainuddin MD, et al
    Early reduction in circulating monocyte count predicts maintenance of remission in patients with rheumatoid arthritis treated with anti-TNF therapy.
    Ann Rheum Dis. 2021 Jun 23. pii: annrheumdis-2021-220642.
    PubMed    


  301. JAIN S, Dhir V, Aggarwal A, Gupta R, et al
    Comparison of two dose escalation strategies of methotrexate in active rheumatoid arthritis: a multicentre, parallel group, randomised controlled trial.
    Ann Rheum Dis. 2021 Jun 10. pii: annrheumdis-2021-220512.
    PubMed     Abstract available


  302. PAULSHUS SUNDLISATER N, Aga AB, Olsen IC, Hammer HB, et al
    Joint tenderness and ultrasound inflammation in DMARD-naive patients with early rheumatoid arthritis.
    Ann Rheum Dis. 2021 Jun 3. pii: annrheumdis-2021-220265.
    PubMed    


  303. CROW MK
    Charles L Christian: model physician scientist and mentor.
    Ann Rheum Dis. 2021;80:685-688.
    PubMed    


  304. ANSALONE C, Cole J, Chilaka S, Sunzini F, et al
    TNF is a homoeostatic regulator of distinct epigenetically primed human osteoclast precursors.
    Ann Rheum Dis. 2021;80:748-757.
    PubMed     Abstract available


  305. HAYER S, Vervoordeldonk MJ, Denis MC, Armaka M, et al
    'SMASH' recommendations for standardised microscopic arthritis scoring of histological sections from inflammatory arthritis animal models.
    Ann Rheum Dis. 2021;80:714-726.
    PubMed     Abstract available


    May 2021
  306. SPARKS JA, Wallace ZS, Seet AM, Gianfrancesco MA, et al
    Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.
    Ann Rheum Dis. 2021 May 28. pii: annrheumdis-2021-220418.
    PubMed     Abstract available


  307. JOHNSON TM, Sayles HR, Baker JF, George MD, et al
    Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis.
    Ann Rheum Dis. 2021 May 28. pii: annrheumdis-2021-220125.
    PubMed     Abstract available


  308. D'ONOFRIO B, De Stefano L, Palermo BL, Xoxi B, et al
    Challenges in the diagnosis of early rheumatoid arthritis in times of COVID-19.
    Ann Rheum Dis. 2021 May 26. pii: annrheumdis-2021-220219.
    PubMed    


  309. LIN TK, Pan LF, Jong GP
    Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'.
    Ann Rheum Dis. 2021 May 26. pii: annrheumdis-2021-220453.
    PubMed    


  310. GONG Z, Zhang F
    Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'.
    Ann Rheum Dis. 2021 May 26. pii: annrheumdis-2021-220494.
    PubMed    


  311. ABTAHI S, Driessen JHM, Burden AM, Souverein PC, et al
    Response to: 'Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study' by Gong and Zhang and Lin et al.
    Ann Rheum Dis. 2021 May 26. pii: annrheumdis-2021-220477.
    PubMed    


  312. TAKANASHI S, Kaneko Y, Takeuchi T
    Elderly patients with comorbidities in the definition of difficult-to-treat rheumatoid arthritis.
    Ann Rheum Dis. 2021 May 7. pii: annrheumdis-2021-220315.
    PubMed    



  313. Correction: Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.
    Ann Rheum Dis. 2021;80:e83.
    PubMed    


  314. ROGIER C, van Dijk BT, Brouwer E, de Jong PHP, et al
    Realising early recognition of arthritis in times of increased telemedicine: the value of patient-reported swollen joints.
    Ann Rheum Dis. 2021;80:668-669.
    PubMed    


  315. SCHULZE-KOOPS H, Krueger K, Vallbracht I, Hasseli R, et al
    Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab.
    Ann Rheum Dis. 2021;80:e67.
    PubMed    


  316. ROMAO VC, Cruz-Machado AR, Fonseca JE
    Response to: 'The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients' by Favalli et al.
    Ann Rheum Dis. 2021;80:e76.
    PubMed    


  317. ZHAO J, Pang R, Wu J, Guo Y, et al
    Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China 'hot spot' versus in US 'hot spot': similarities and differences.
    Ann Rheum Dis. 2021;80:e63.
    PubMed    


  318. MOENTADJ R, Wang Y, Bowerman K, Rehaume L, et al
    Streptococcus species enriched in the oral cavity of patients with RA are a source of peptidoglycan-polysaccharide polymers that can induce arthritis in mice.
    Ann Rheum Dis. 2021;80:573-581.
    PubMed     Abstract available


  319. KAJIO N, Takeshita M, Suzuki K, Kaneda Y, et al
    Anti-centromere antibodies target centromere-kinetochore macrocomplex: a comprehensive autoantigen profiling.
    Ann Rheum Dis. 2021;80:651-659.
    PubMed     Abstract available


    April 2021
  320. ROONGTA R, Chattopadhyay A, Ghosh A
    Correspondence on 'Onset of rheumatoid arthritis after COVID-19: coincidence or connected?'
    Ann Rheum Dis. 2021 Apr 27. pii: annrheumdis-2021-220479.
    PubMed    


  321. DERKSEN VFAM, van der Woude D
    Response to: 'Correspondence on 'Onset of rheumatoid arthritis after COVID-19: coincidence or connected?'' by Roongta et al.
    Ann Rheum Dis. 2021 Apr 27. pii: annrheumdis-2021-220516.
    PubMed    


  322. INGEGNOLI F, Cincinelli G, Luppino AF, Favalli EG, et al
    Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy.
    Ann Rheum Dis. 2021 Apr 13. pii: annrheumdis-2021-220142.
    PubMed    


  323. MIYAZAKI Y, Nakano K, Nakayamada S, Kubo S, et al
    Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.
    Ann Rheum Dis. 2021 Apr 7. pii: annrheumdis-2020-219699.
    PubMed     Abstract available


  324. XIE W, Huang H, Li G, Hao Y, et al
    Dynamical trajectory of glucocorticoids tapering and discontinuation in patients with rheumatoid arthritis commencing glucocorticoids with csDMARDs: a real-world data from 2009 to 2020.
    Ann Rheum Dis. 2021 Apr 2. pii: annrheumdis-2021-220112.
    PubMed     Abstract available


  325. STOUTEN V, Westhovens R, Pazmino S, De Cock D, et al
    Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial.
    Ann Rheum Dis. 2021 Apr 2. pii: annrheumdis-2020-219825.
    PubMed     Abstract available


  326. SO H, Cheng IT, Lau SL, Chow E, et al
    Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial.
    Ann Rheum Dis. 2021 Apr 2. pii: annrheumdis-2021-219846.
    PubMed     Abstract available


  327. GUPTA L, Misra DP, Agarwal V, Balan S, et al
    Response to: 'Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort' by Costa et al.
    Ann Rheum Dis. 2021;80:e47.
    PubMed    


    March 2021
  328. FELTEN R, Devauchelle-Pensec V, Seror R, Duffau P, et al
    Interleukin 6 receptor inhibition in primary Sjogren syndrome: a multicentre double-blind randomised placebo-controlled trial.
    Ann Rheum Dis. 2021;80:329-338.
    PubMed     Abstract available


  329. BAER AN, Gottenberg JE, St Clair EW, Sumida T, et al
    Efficacy and safety of abatacept in active primary Sjogren's syndrome: results of a phase III, randomised, placebo-controlled trial.
    Ann Rheum Dis. 2021;80:339-348.
    PubMed     Abstract available


  330. AKIYAMA S, Hamdeh S, Micic D, Sakuraba A, et al
    Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis.
    Ann Rheum Dis. 2021;80:384-391.
    PubMed     Abstract available


  331. LIEW JW, Graef ER
    Rheumatic disease and COVID-19.
    Ann Rheum Dis. 2021;80:e43.
    PubMed    


  332. MONTI S, Montecucco C
    Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak.
    Ann Rheum Dis. 2021;80:e40.
    PubMed    


  333. WALLACE B, Washer L, Marder W, Kahlenberg JM, et al
    Patients with lupus with COVID-19: University of Michigan experience.
    Ann Rheum Dis. 2021;80:e35.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Rheumatoid Arthritis is free of charge.